What is the market's earnings forecast for Hyperfine next quarter?

What is the revenue and EPS growth rate for Hyperfine year over year?

Did Hyperfine beat or miss consensus estimates last quarter?

What factors drove the changes in Hyperfine's revenue and profit?

What guidance did Hyperfine's management provide for the next earnings period?

What is Hyperfine's latest dividend and current dividend yield?

What does Hyperfine do and what are its main business segments?

What were the key takeaways from Hyperfine's earnings call?

- **Revenue Acceleration**: Q3 $3.4M (+27% QoQ), Q4 guided $5-6M (+60% QoQ), full year $13-14M (+137% YoY)
- **Margin Expansion**: Gross margin 53.8% (up 450bp QoQ), 2025 full year 49-51% (up 430bp YoY)
- **Pipeline Diversification**: 3 verticals (hospitals, offices, international) with 8 units sold in Q3, 10 language OPTI AI rollouts
- **Cash Efficiency**: Q3 cash burn $5.9M (-27% QoQ), 2025 full year $29-31M (-22% YoY), runway to H2 2027 with $20M raise
- **Strategic Wins**: France Uni HA tender, India regulatory pending, 10 language OPTI AI launch

**【CEO Summary Section】**
- Q3 2025 revenue reached $3.4 million, up 27% sequentially, driven by next-generation Swoop system sales and a record average selling price of $361,000.
- Gross margin improved to 53.8%, up 450 basis points sequentially, due to higher ASP and cost optimization.
- Launched OPTI AI software in 10 languages, with CE and UKCA approvals, and expanded into international markets like France and India.
- Diversified pipeline across 3 verticals: hospitals (IDN deals), neurology offices (Neuro Net partnerships), and international (tender processes).
- Q4 2025 revenue guidance: $5-6 million (60% sequential growth), full year 2025: $13-14 million.

**【CFO Commentary】**
- Q3 2025 financials: 
  - Revenue: $3.4M (27% sequential growth)
  - Gross profit: $1.8M (53.8% margin)
  - R&D: $4.0M (11% sequential decline)
  - SGA: $6.7M (4.7% sequential increase)
  - Net loss: $11.0M ($0.14/share)
  - Cash burn (excl. financing): $5.9M (27% sequential decline)
- Full year 2025 guidance: 
  - Revenue: $13-14M (137% YoY growth)
  - Gross margin: 49-51% (430bp YoY expansion)
  - Cash burn: $29-31M (22% YoY decline)
  - Cash runway extended to H2 2027 with $20M October equity raise.

**【Q&A Highlights】**
- **Pipeline Segmentation**: 
  - Hospitals: 8 units sold in Q3, expanding to 2+ hospitals per IDN
  - Offices: 2 large neurology practices in pilot, 10 language OPTI AI rollouts
  - International: France (Uni HA tender), India (pending regulatory)
- **Growth Drivers**: 
  - Hospital: 1-1.5 year ROI vs. 3-4 years for high-field MRI
  - Office: 15% ASP premium, 100M+ neurology patients
  - International: 10 language support, 2026 CE Mark for urology
- **2026 Outlook**: 
  - Q4 2025 results will set 2026 trajectory; no guidance yet
  - Focus on scaling commercial infrastructure, not R&D

Hyperfine, Inc. (HYPR) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

HYPR

HYPR fundamentals

You can ask Aime